Immunohistochemical study of matrix metalloproteinase 9 and tissue inhibitor of matrix metalloproteinase 1 in benign and malignant breast tissue - Strong expression in intraductal carcinomas of the breast

Tumor Biology

Volumn 30, Issue 5-6, 2009, Pages 257-264

  Rahko, E ^a   Kauppila, S ^a   Paakko P ^a   Blanco, G ^a   Apaja Sarkkinen, M ^a   Talvensaari Mattila, A ^a   Turpeenniemi Hujanen, T ^a   Jukkola, A ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Atypical hyperplasia; Breast cancer; Carcinogenesis; Ductal carcinomain situ; Matrix metalloproteinases; MMP 9; TIMP 1

Indexed keywords

GELATINASE B; INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST HYPERPLASIA; CANCER GRADING; CANCER INFILTRATION; CANCER INVASION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; EARLY DIAGNOSIS; ENZYME ANALYSIS; ENZYME INHIBITION; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTRADUCTAL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 73749087614     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1159/000253662     Document Type: Article

References (39)

1. Chambers AF, Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997; 89: 1260-1270.
2. Duffy MJ, McCarthy K: Matrix metalloproteinases in cancer: prognostic markers and targets for therapy. Int J Oncol 1998; 12: 1343-1348.
3. Sternlicht MD, Werb Z: How matrix metalloproteinases regulate cell behaviour. Annu Rev Cell Dev Biol 2001; 17: 463-516.
4. John A, Tuszynski G: The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 2001; 7: 14-23.
5. Sheu BC, Hsu SM, Ho HN, Lien HC, Huan SC, Lin RH: A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res 2001; 61: 237-242.
6. Greene J, Wang M, Celiker MY, Liu YE, Sang QX, Goldberg ID, Shi YE: Stimulation of mammary tumorigenesis by systemic tissue inhibitor of matrix metalloproteinase 4 gene delivery. Cancer Res 2001; 61: 2365-2370.
7. Cox G, Jones JL, O'Byrne KJ: Matrix metalloproteinase and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res 2000; 6: 2349-2355.
8. Sier CF, Kubben FJ, Ganesh S, Heerding MM, Griffioen G, Hanemaaijer R, Van Krieken JH, Lamers CB, Verspaget HW: Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 1996; 74: 413-417.
9. Foukas AF, Deshmukh NS, Grimer RJ, Mangham DC, Mangos EG, Taylor S: Stage- IIB osteosarcomas around the knee. A study of MMP-9 in surviving tumour cells. J Bone Joint Surg Br 2002; 84: 706-711.
10. Ruokolainen H, Pääkkö P, Turpeenniemi- Hujanen T: Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: a potential marker for prognosis. Clin Cancer Res 2004; 10: 3110-3116. (Pubitemid 38619691)
11. Rahko E, Jukkola A, Melkko J, Pääkkö P, Bloigu R, Talvensaari-Mattila A, Turpeenniemi-Hujanen T: Matrix metalloproteinase MMP-9 immunoreactive protein has modest prognostic value in locally advanced breast carcinoma patients treated with an adjuvant antiestrogen therapy. Anticancer Res 2004; 24: 4247-4254.
12. Scorilas A, Karameris A, Arnogiannaki N, Ardavanis A, Bassilopoulos P, Trangas T, Talieri M: Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Br J Cancer 2001; 84: 1488-1496.
13. Van't Veer L, Dai H, Van De Vijver M, He Y, Hart A, Mao M, Peterse H, Van Der Kooy K, Marton M, Witteween A, Schreiber G, Kerkhoven R, Roberts C, Linsley P, Bernards R, Friend S: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
14. Mannello F, Gazzanelli G: Tissue inhibitors of matrix metalloproteinases and programmed cell death: conundrums, controversies and potential implications. Apoptosis 2001; 6: 479-482.
15. Nagase H, Visse R, Murphy G: Structure and functions of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69: 562-573.
16. Luparello C, Anazato G, Garella C, Pucci- Minafra I: Tissue inhibitor of metalloprotease (TIMP)-1 and proliferative behaviour of clonal breast cancer cells. Breast Cancer Res Treat 1999; 54: 235-244.
17. Liu XW, Taube ME, Jung KK, Dong Z, Lee YJ, Roshy S, Sloane BF, Fridman R, Kim HR: Tissue inhibitor of matrix metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase- 1. Cancer Res 2005; 65: 898-906.
18. Schrohl AS, Holten-Andersen MN, Peters HA, Look MP, Meijer-van Gelder ME, Klijn JG, Brunner N, Foekens JA: Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res 2004; 10: 2289-2298.
19. Sieuwerts AM, Usher PA, Meijer-van Gelder ME, Timmermans M, Martens JWM, Brunner N, Klijn JG, Offenberg H, Foekens JA: Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer. Clin Chem 2007; 53: 1280-1288.
20. Talvensaari-Mattila A, Turpeenniemi-Hujanen T: High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinoma. Breast Cancer Res Treat 2005; 89: 29-34.
21. Wurtz S, Schrohl AS, Mouridsen H, Brunner N: TIMP-1 as a tumor marker in breast cancer - an update. Acta Oncol 2008; 47: 580-590.
22. Ottesen GL, Christensen IJ, Larsen JK, Christiansen J, Hansen B, Andersen JA: DNA analysis of in situ ductal carcinoma of the breast via flow cytometry. Cytometry 1995; 22: 168-176.
23. Ma Xj, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, Payette T, Pistone M, Stecker K, Zhang BM, Zhou YX, Varnholt H, Smith B, Gadd M, Chatfield E, Kessler J, Baer TM, Erlander MG, Sgroi DC: Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 2003; 100: 5974-5979.
24. Burstein HJ, Polyak K, Wong JS, Lester S, Kaelin CM: Ductal carcinoma in situ of the breast. N Engl J Med 2004; 350: 1430-1441.
25. Boecker W, Buerger H, Schmitz K, Ellis IA, Van Diest PJ, Sinn HP, Geradts J, Diallo R, Poremba C, Herbst H: Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high-molecular-weight cytokeratin expression patterns. J Pathol 2001; 195: 415-421.
26. Ernster VL, Ballard-Barbash R, Barlow WE, Zheng Y, Weawer DL, Cutter G, Yankaskas BC, Rosenberg R, Carney PA, Kerlikowske K, Taplin SH, Urban N, Geller BM: Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 2002; 94: 1546-1554.
27. Brummer O, Athar S, Riethdorf L, Löning T, Herbst H: Matrix-metalloproteinases 1, 2, and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridization study. Virchows Arch 1999; 435: 566-573.
28. Gonzalez LO, Corte MD, Vazquez J, Junguera S, Sanchez R, Vina A, Rodriguez JC, Lamelas ML, Vizoso F: Study of matrix metalloproteinases and their tissue inhibitors in ductal in situ carcinomas of the breast. Histopathology 2008; 53: 403-415.
29. Zhao YG, Xiao AZ, Park HI, Newcomer RG, Yan M, Man YG, Heffelfinger SC, Sang QX: Endometase/matrilysin-2 in human breast ductal carcinoma in situ and its inhibition by tissue inhibitors of metalloproteinases-2 and -4: a putative role in the initiation of breast cancer invasion. Cancer Res 2004; 64: 590-598.
30. Tavassoli FA, Devilee P (eds): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, IARC Press, 2003, p 66.
31. Sang QX: Complex role of matrix metalloproteinases in angiogenesis. Cell Res 1998; 3: 171-177.
32. Lambert E, Dassé E, Haye B, Petitfrère E: TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004; 49: 187-198.
33. Lee KS, Rha SY, Kim SJ, Kim JH, Roh JK, Kim BS, Chung HC: Sequential activation and production of matrix metalloproteinase-2 during breast cancer progression. Clin Exp Metastasis 1996; 14: 512-519.
34. Talvensaari-Mattila A, Pääkkö P, Höyhtyä M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer 1998; 83: 1153-1162.
35. Talvensaari-Mattila A, Pääkkö P, Turpeenniemi- Hujanen T: Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer 2003; 89: 270-275.
36. Nielsen BS, Rank F, Lopez JM, Balbin M, Vizoso F, Lund LR, Dano K, Lopez-Otin C: Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas. Cancer Res 2001; 61: 7091-7100.
37. Poola I, DeWitty RL, Marshalleck JJ, Bhatnagar R, Abraham J, Leffal LD: Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysis. Nat Med 2005; 11: 481-485.
38. Ottesen GL: Carcinoma in situ of the female breast. A clinico-pathological, immunohistochemical, and DNA ploidy study. APMIS Suppl 2003; 111: 5-68.
39. Fitzgibbons PL, Henson DE, Hutter RV: Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists. Arch Pathol Lab Med 1998; 122: 1053-1055.